메뉴 건너뛰기




Volumn 12, Issue SUPPL. 7, 2006, Pages

Importance of early diagnosis and treatment of osteoporosis to prevent fractures

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CAROTENE; CREATINE; DEOXYPYRIDINOLINE; GLUCOCORTICOID; HYDROCORTISONE; IBANDRONIC ACID; OSTEOCALCIN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; PROCOLLAGEN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; RALOXIFENE; RISEDRONIC ACID; THYROTROPIN; VITAMIN D;

EID: 33646789418     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (33)

References (51)
  • 1
    • 77952915431 scopus 로고    scopus 로고
    • National Osteoporosis Foundation. Physician's Guide: Pharmacologic Options. Available at: http://www.nof.org/physguide/pharmacologic.htm. Accessed February 23, 2006.
    • Physician's Guide: Pharmacologic Options
  • 2
    • 84884624502 scopus 로고    scopus 로고
    • Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey. Available at: http://www.cdc.gov/nchs/data/nhanes/ databriefs/osteoporosis.pdf. Accessed February 23, 2006.
    • National Health and Nutrition Examination Survey
  • 3
    • 33646772240 scopus 로고    scopus 로고
    • MedPAC. Medicare Beneficiary Demographics. Available at: http://www.medpac.gov/publications/congressional_reports/Jun04DataBookSec1.pdf. Accessed February 23, 2006.
    • Medicare Beneficiary Demographics
  • 4
    • 0030930232 scopus 로고    scopus 로고
    • The crippling consequences of fractures and their impact on quality of life
    • discussion 17S-19S
    • Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med. 1997;103:12S-17S; discussion 17S-19S.
    • (1997) Am J Med , vol.103
    • Cooper, C.1
  • 5
    • 1642401284 scopus 로고    scopus 로고
    • Treatment of osteoporosis: Why, whom, when and how to treat. The single most important consideration is the individual's absolute risk of fracture
    • Seeman E, Eisman JA. Treatment of osteoporosis: why, whom, when and how to treat. The single most important consideration is the individual's absolute risk of fracture. Med J Aust. 2004;180:298-303.
    • (2004) Med J Aust , vol.180 , pp. 298-303
    • Seeman, E.1    Eisman, J.A.2
  • 6
    • 0035857351 scopus 로고    scopus 로고
    • Osteoporosis prevention, diagnosis, and therapy
    • NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785-795.
    • (2001) JAMA , vol.285 , pp. 785-795
  • 10
    • 33646761011 scopus 로고    scopus 로고
    • American Medical Association. Osteoporosis Management. Pathophysiology of Osteoporosis. Available at: http://www.ama-cmeonline.corn/osteo_mgmt/module03/ 01cme/02.htm. Accessed February 23, 2006.
    • Pathophysiology of Osteoporosis
  • 11
    • 7844248653 scopus 로고    scopus 로고
    • Biochemical markers of bone turnover. A look at laboratory tests that reflect bone status
    • Rosen CJ, Tenenhouse A. Biochemical markers of bone turnover. A look at laboratory tests that reflect bone status. Postgrad Med. 1998;104:101-102, 107-110, 113-114.
    • (1998) Postgrad Med , vol.104 , pp. 101-102
    • Rosen, C.J.1    Tenenhouse, A.2
  • 12
    • 0034022318 scopus 로고    scopus 로고
    • Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis
    • Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA III, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000;15:721-739.
    • (2000) J Bone Miner Res , vol.15 , pp. 721-739
    • Klotzbuecher, C.M.1    Ross, P.D.2    Landsman, P.B.3    Abbott III, T.A.4    Berger, M.5
  • 13
    • 0035900949 scopus 로고    scopus 로고
    • Risk of new vertebral fracture in the year following a fracture
    • Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA. 2001;285:320-323.
    • (2001) JAMA , vol.285 , pp. 320-323
    • Lindsay, R.1    Silverman, S.L.2    Cooper, C.3
  • 14
    • 17844380250 scopus 로고    scopus 로고
    • Bone density and the risk of fractures: Should treatment thresholds vary by race?
    • Acheson LS. Bone density and the risk of fractures: should treatment thresholds vary by race? JAMA. 2005;293:2151-2154.
    • (2005) JAMA , vol.293 , pp. 2151-2154
    • Acheson, L.S.1
  • 15
    • 0035281988 scopus 로고    scopus 로고
    • Osteoporosis: Part I. Evaluation and assessment
    • South-Paul JE. Osteoporosis: part I. Evaluation and assessment. Am Fam Physician. 2001;63:897-904, 908.
    • (2001) Am Fam Physician , vol.63 , pp. 897-904
    • South-Paul, J.E.1
  • 16
    • 33646758930 scopus 로고    scopus 로고
    • National Osteoporosis Foundation. Reimbursement of Bone Mineral Density Test. Available at: http://www.nof.org/professionals/reimbursement/. Accessed February 23, 2006.
    • Reimbursement of Bone Mineral Density Test
  • 17
    • 0035852034 scopus 로고    scopus 로고
    • Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: Results from the National Osteoporosis Risk Assessment
    • Siris ES, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA. 2001;286:2815-2822.
    • (2001) JAMA , vol.286 , pp. 2815-2822
    • Siris, E.S.1    Miller, P.D.2    Barrett-Connor, E.3
  • 18
    • 2442654174 scopus 로고    scopus 로고
    • Bone mineral density thresholds for pharmacological intervention to prevent fractures
    • Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004;164:1108-1112.
    • (2004) Arch Intern Med , vol.164 , pp. 1108-1112
    • Siris, E.S.1    Chen, Y.T.2    Abbott, T.A.3
  • 19
    • 0019505458 scopus 로고
    • Differential changes in bone mineral density of the appendicular and axial skeleton with aging: Relationship to spinal osteoporosis
    • Riggs BL, Wahner HW, Dunn WL, Mazess RB, Offord KP, Melton LJ III. Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis. J Clin Invest. 1981;67:328-335.
    • (1981) J Clin Invest , vol.67 , pp. 328-335
    • Riggs, B.L.1    Wahner, H.W.2    Dunn, W.L.3    Mazess, R.B.4    Offord, K.P.5    Melton III, L.J.6
  • 20
    • 0029885623 scopus 로고    scopus 로고
    • Clinical utility of bone mass measurements in adults: Consensus of an international panel
    • The Society for Clinical Densitometry
    • Miller PD, Bonnick SL, Rosen CJ, et al. Clinical utility of bone mass measurements in adults: consensus of an international panel. The Society for Clinical Densitometry. Semin Arthritis Rheum. 1996;25:361-372.
    • (1996) Semin Arthritis Rheum , vol.25 , pp. 361-372
    • Miller, P.D.1    Bonnick, S.L.2    Rosen, C.J.3
  • 21
    • 0028963682 scopus 로고
    • Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group
    • Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1995;332:767-773.
    • (1995) N Engl J Med , vol.332 , pp. 767-773
    • Cummings, S.R.1    Nevitt, M.C.2    Browner, W.S.3
  • 22
    • 0030594825 scopus 로고    scopus 로고
    • Fall-related factors and risk of hip fracture: The EPIDOS prospective study
    • Dargent-Molina P, Favier F, Grandjean H, et al. Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet. 1996;348:145-149.
    • (1996) Lancet , vol.348 , pp. 145-149
    • Dargent-Molina, P.1    Favier, F.2    Grandjean, H.3
  • 23
    • 0033829969 scopus 로고    scopus 로고
    • A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study
    • PROOF Study Group
    • Chesnut CH III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000;109:267-276.
    • (2000) Am J Med , vol.109 , pp. 267-276
    • Chesnut III, C.H.1    Silverman, S.2    Andriano, K.3
  • 24
    • 0033581212 scopus 로고    scopus 로고
    • Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
    • Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators
    • Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637-645.
    • (1999) JAMA , vol.282 , pp. 637-645
    • Ettinger, B.1    Black, D.M.2    Mitlak, B.H.3
  • 25
    • 18544381541 scopus 로고    scopus 로고
    • Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial
    • Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002;87:3609-3617.
    • (2002) J Clin Endocrinol Metab , vol.87 , pp. 3609-3617
    • Delmas, P.D.1    Ensrud, K.E.2    Adachi, J.D.3
  • 26
    • 0033552255 scopus 로고    scopus 로고
    • Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial
    • Vertebral Efficacy With Risedronate Therapy (VERT) Study Group
    • Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344-1352.
    • (1999) JAMA , vol.282 , pp. 1344-1352
    • Harris, S.T.1    Watts, N.B.2    Genant, H.K.3
  • 27
    • 12944291524 scopus 로고    scopus 로고
    • Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
    • Vertebral Efficacy with Risedronate Therapy (VERT) Study Group
    • Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11:83-91.
    • (2000) Osteoporos Int , vol.11 , pp. 83-91
    • Reginster, J.1    Minne, H.W.2    Sorensen, O.H.3
  • 28
    • 0004851872 scopus 로고    scopus 로고
    • Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
    • Fracture Intervention Trial Research Group
    • Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535-1541.
    • (1996) Lancet , vol.348 , pp. 1535-1541
    • Black, D.M.1    Cummings, S.R.2    Karpf, D.B.3
  • 29
    • 0032583492 scopus 로고    scopus 로고
    • Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
    • Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-2082.
    • (1998) JAMA , vol.280 , pp. 2077-2082
    • Cummings, S.R.1    Black, D.M.2    Thompson, D.E.3
  • 30
    • 0036119735 scopus 로고    scopus 로고
    • Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs
    • Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002;112:281-289.
    • (2002) Am J Med , vol.112 , pp. 281-289
    • Cummings, S.R.1    Karpf, D.B.2    Harris, F.3
  • 31
    • 0036133350 scopus 로고    scopus 로고
    • Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy
    • Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res. 2002;17:1-10.
    • (2002) J Bone Miner Res , vol.17 , pp. 1-10
    • Sarkar, S.1    Mitlak, B.H.2    Wong, M.3    Stock, J.L.4    Black, D.M.5    Harper, K.D.6
  • 32
    • 4444238224 scopus 로고    scopus 로고
    • Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: Greater increases in bone mineral density do not relate to greater decreases in fracture risk
    • Watts NB, Cooper C, Lindsay R, et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom. 2004;7:255-261.
    • (2004) J Clin Densitom , vol.7 , pp. 255-261
    • Watts, N.B.1    Cooper, C.2    Lindsay, R.3
  • 33
    • 14644401066 scopus 로고    scopus 로고
    • The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy
    • Solomon E. The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy. Mayo Clin Proc. 2005;80:379-388.
    • (2005) Mayo Clin Proc , vol.80 , pp. 379-388
    • Solomon, E.1
  • 34
    • 0034601803 scopus 로고    scopus 로고
    • Investigation and treatment of osteoporosis in patients with fragility fractures
    • Hajcsar EE, Hawker G, Bogoch ER. Investigation and treatment of osteoporosis in patients with fragility fractures. CMAJ. 2000;163:819-822.
    • (2000) CMAJ , vol.163 , pp. 819-822
    • Hajcsar, E.E.1    Hawker, G.2    Bogoch, E.R.3
  • 35
    • 0030763532 scopus 로고    scopus 로고
    • Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older
    • Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997;337:670-676.
    • (1997) N Engl J Med , vol.337 , pp. 670-676
    • Dawson-Hughes, B.1    Harris, S.S.2    Krall, E.A.3    Dallal, G.E.4
  • 36
    • 33646809048 scopus 로고    scopus 로고
    • National Institutes of Health. Health Topics. Osteoporosis Overview. Available at: http://www.niams.nih.gov/bone/hi/overview.htm. Accessed February 23, 2006.
    • Health Topics. Osteoporosis Overview
  • 37
    • 0029884643 scopus 로고    scopus 로고
    • Bisphosphonates: Mechanisms of action
    • Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest. 1996;97:2692-2696.
    • (1996) J Clin Invest , vol.97 , pp. 2692-2696
    • Rodan, G.A.1    Fleisch, H.A.2
  • 38
    • 12144289279 scopus 로고    scopus 로고
    • Ten years' experience with alendronate for osteoporosis in post-menopausal women
    • Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in post-menopausal women. N Engl J Med. 2004;350:1189-1199.
    • (2004) N Engl J Med , vol.350 , pp. 1189-1199
    • Bone, H.G.1    Hosking, D.2    Devogelaer, J.P.3
  • 39
    • 0037291756 scopus 로고    scopus 로고
    • Long-term efficacy of risedronate: A 5-year placebo-controlled clinical experience
    • Sorensen OH, Crawford GM, Mulder H, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone. 2003;32:120-126.
    • (2003) Bone , vol.32 , pp. 120-126
    • Sorensen, O.H.1    Crawford, G.M.2    Mulder, H.3
  • 40
    • 11144354206 scopus 로고    scopus 로고
    • Efficacy of risedronate on clinical vertebral fractures within six months
    • Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin. 2004;20:433-439.
    • (2004) Curr Med Res Opin , vol.20 , pp. 433-439
    • Roux, C.1    Seeman, E.2    Eastell, R.3
  • 41
    • 1342281219 scopus 로고    scopus 로고
    • Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis
    • Harrington JT, Ste-Marie LG, Brandi ML, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004;74:129-135.
    • (2004) Calcif Tissue Int , vol.74 , pp. 129-135
    • Harrington, J.T.1    Ste-Marie, L.G.2    Brandi, M.L.3
  • 42
    • 0035253489 scopus 로고    scopus 로고
    • Effect of risedronate on the risk of hip fracture in elderly women
    • Hip Intervention Program Study Group
    • McClung MR, Geusens P, Miller PD, et al; Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344:333-340.
    • (2001) N Engl J Med , vol.344 , pp. 333-340
    • McClung, M.R.1    Geusens, P.2    Miller, P.D.3
  • 43
    • 4243722312 scopus 로고    scopus 로고
    • Rapid and sustained effect of risedronate in reducing hip fracture risk in elderly women with osteoporosis
    • Abstract 1042
    • Seeman E, et al. Rapid and sustained effect of risedronate in reducing hip fracture risk in elderly women with osteoporosis. J Bone Miner Res. 2000;15(suppl 1):S149, Abstract 1042.
    • (2000) J Bone Miner Res , vol.15 , Issue.SUPPL. 1
    • Seeman, E.1
  • 44
    • 4544262219 scopus 로고    scopus 로고
    • Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
    • Chesnut CH III, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241-1249.
    • (2004) J Bone Miner Res , vol.19 , pp. 1241-1249
    • Chesnut III, C.H.1    Skag, A.2    Christiansen, C.3
  • 45
    • 22744433117 scopus 로고    scopus 로고
    • Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-Year results from the MOBILE study
    • Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res. 2005;20:1315-1322.
    • (2005) J Bone Miner Res , vol.20 , pp. 1315-1322
    • Miller, P.D.1    McClung, M.R.2    Macovei, L.3
  • 46
    • 33646188845 scopus 로고    scopus 로고
    • East Hanover, NJ: Novartis Pharmaceuticals Corp
    • Miacalcin [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2003.
    • (2003) Miacalcin [Package Insert]
  • 48
    • 23644458909 scopus 로고    scopus 로고
    • Benefit-risk assessment of raloxifene in postmenopausal osteoporosis
    • Cranney A, Adachi JD. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis. Drug Saf. 2005;28:721-730.
    • (2005) Drug Saf , vol.28 , pp. 721-730
    • Cranney, A.1    Adachi, J.D.2
  • 49
    • 0037527036 scopus 로고    scopus 로고
    • Indianapolis, IN: Eli Lilly and Company
    • Forteo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2002.
    • (2002) Forteo [Package Insert]
  • 50
    • 0035837553 scopus 로고    scopus 로고
    • Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
    • Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-1441.
    • (2001) N Engl J Med , vol.344 , pp. 1434-1441
    • Neer, R.M.1    Arnaud, C.D.2    Zanchetta, J.R.3
  • 51
    • 1842867053 scopus 로고    scopus 로고
    • Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial
    • Anderson GL, Limacher M, Assaf AR, et al; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-1712.
    • (2004) JAMA , vol.291 , pp. 1701-1712
    • Anderson, G.L.1    Limacher, M.2    Assaf, A.R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.